Skip to content

The peptide intelligence library

Ask anything about peptides.

Every answer names the evidence tier it rests on, and says plainly when the research is thin.

Free to ask. No account required. Not medical advice.

THE RESEARCH ATLAS

From molecule to evidence.

Explore the library
Compound profiles
149

Small chains.
A world of research.

STRUCTURE
FUNCTION
EVIDENCE
Research areas
21

Across human biology.

Citations indexed
554

Connected to the source.

Evidence tiers
4
Understand the grades
  1. Clinical
  2. Human-limited
  3. Animal
  4. Anecdotal

Evidence grading

Four tiers. No blending, no averaging, no hedging.

Most sources flatten a rodent study and a randomised trial into the same confident sentence. We refuse to. Each statement on a profile is tagged with the strength of the evidence behind it, and the tag travels with the claim wherever it appears.

Clinical

15 profiles

Findings supported by randomised, controlled trials in humans, with pre-registered endpoints and published results.

Randomised human trialsStrongest available signal

Human-limited

61 profiles

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Small or observationalSuggestive, not settled

Animal

54 profiles

Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.

Preclinical modelsMechanism only

Anecdotal

19 profiles

Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.

Reports and self-reportLowest confidence

A worked example

Two compounds in this registry are described online in almost identical language. One has twenty-four randomised trials and published cardiovascular outcome data. The other has ninety-six rodent studies and no completed randomised trial in humans. Both are catalogued here with the difference stated on the first line rather than buried in the footnotes.

Clinical

Semaglutide

24 randomised trials

Animal

BPC-157

0 randomised trials

Member tools

Reference on one side. Your own record on the other.

The library is free and always will be. If you keep a personal research log, these tools live alongside it private by default, exportable at any time.

Today · MondayPrivate

Scheduled

  • 07:30Morning entryLogged
  • 12:00Midday noteLogged
  • 21:00Evening entryDue

Vials

Vial A62%
Vial B28%
Vial C91%

Today

One screen for what is scheduled, what is due, and what was logged. Built to be glanced at, not managed.

Vial inventory

Reconstitution records, remaining volume, and expiry tracking, kept per vial rather than per compound.

Bloodwork

Panels over time, plotted against your own baseline instead of a population reference range.

Research assistant

Ask a question, get an answer that cites the tier it came from and says so when the literature is thin.

Independence

Nobody pays us to say anything.

A reference database is only worth reading if its incentives are boring. Ours are: members fund the tools, the library stays free, and no third party has a say in a grade.

No vendor relationships

We do not sell compounds, take affiliate revenue, accept sponsored placements, or link to suppliers. There is no version of this site where a manufacturer can buy a better grade.

No protocol recommendations

We describe what has been studied. We do not tell you what to take, how much, or when. That line is the whole point, and we hold it even when readers ask us to cross it.

Negative results kept

Trials that failed stay on the profile with the same prominence as trials that succeeded. A discontinued phase 3 programme is information, not an omission.

Corrections in the open

Every profile carries a revision history. When we are wrong, the change is dated, attributed, and visible rather than quietly edited away.

Read the evidence. Draw your own conclusions.

The library opens without an account and without a paywall. Start anywhere the grade is always on the first line.